摘要: Ovarian cancer (OC) is the most important cause of gynecological cancer-related mortality, with majority women presenting advanced disease. Although surgery and chemotherapy can improve survival, 5-year survival rates remain ominously low at 45%. Novel therapies are urgently needed. The presence T cells in OC tumor microenvironment correlated improved progression-free overall while regulatory expression T-cell inhibitory molecules a poor prognosis. These data indicate that immunotherapy could hold promise improving treatment OC. In this review, we will discuss rational immunotherapy, highlight current results vaccines, adoptive therapy immunomodulatory agents summarize immune effects selected chemotherapeutic radiotherapeutic agents.
annalsofoncology.org
core.ac.uk
oup.com
oxfordjournals.org
sci-hub.se 参考文章(77)
Tyler Curiel, Suzanne Thibodeaux, Suzanne Thibodeaux, Vincent Hurez, Shawna Wall, Benjamin Daniel, Aijie Liu, Weiping Zou, Leslie Wood, Sri Lakshmi Pandeswara, Lishi Sun, Interferon-α augments the clinical efficacy of regulatory T cell depletion in ovarian cancer through direct and indirect T cell effects (VAC3P.941) Journal of Immunology. ,vol. 192, ,(2014)
G H Windbichler, H Hausmaninger, W Stummvoll, A H Graf, C Kainz, J Lahodny, U Denison, E Müller-Holzner, C Marth, Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. British Journal of Cancer. ,vol. 82, pp. 1138- 1144 ,(2000) , 10.1054/BJOC.1999.1053
Paul Sabbatini, David Spriggs, Carol Aghajanian, Martee Hensley, William Tew, Jason Konner, Kathryn Bell-McGuinn, Margrit Juretzka, Alexia Iasonos, Consolidation strategies in ovarian cancer: Observations for future clinical trials Gynecologic Oncology. ,vol. 116, pp. 66- 71 ,(2010) , 10.1016/J.YGYNO.2009.09.016
Werner Robert Bezwoda, Leslie Seymour, Roger Dansey, Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer Cancer. ,vol. 64, pp. 1029- 1033 ,(1989) , 10.1002/1097-0142(19890901)64:5<1029::AID-CNCR2820640511>3.0.CO;2-#
Haoyu Sun, Cheng Sun, Weihua Xiao, Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations Cytokine. ,vol. 65, pp. 33- 41 ,(2014) , 10.1016/J.CYTO.2013.09.016
Sarah F. Adams, Douglas A. Levine, Mark G. Cadungog, Rachel Hammond, Andrea Facciabene, Narciso Olvera, Stephen C. Rubin, Jeff Boyd, Phyllis A. Gimotty, George Coukos, Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. ,vol. 115, pp. 2891- 2902 ,(2009) , 10.1002/CNCR.24317
James L. Gulley, Therapeutic vaccines: the ultimate personalized therapy? Human Vaccines & Immunotherapeutics. ,vol. 9, pp. 219- 221 ,(2013) , 10.4161/HV.22106
Christina S. Chu, Jean Boyer, Daniel S. Schullery, Phyllis A. Gimotty, Victoria Gamerman, James Bender, Bruce L. Levine, George Coukos, Stephen C. Rubin, Mark A. Morgan, Robert H. Vonderheide, Carl H. June, Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission Cancer Immunology, Immunotherapy. ,vol. 61, pp. 629- 641 ,(2012) , 10.1007/S00262-011-1081-8
Steven A Rosenberg, James C Yang, Nicholas P Restifo, Cancer immunotherapy: moving beyond current vaccines Nature Medicine. ,vol. 10, pp. 909- 915 ,(2004) , 10.1038/NM1100
Panagiotis Karagiannis, Amy E Gilbert, Frank O Nestle, Sophia N Karagiannis, IgG4 antibodies and cancer-associated inflammation: Insights into a novel mechanism of immune escape. OncoImmunology. ,vol. 2, pp. 1- 3 ,(2013) , 10.4161/ONCI.24889